ERYLIK

This brand name is authorized in Estonia, France, Hong Kong SAR China, Tunisia.

Active ingredients

The drug ERYLIK contains a combination of these active pharmaceutical ingredients (APIs):

1	Erythromycin UNII 63937KV33D - ERYTHROMYCIN
	Erythromycin exerts its antimicrobial action by binding to the 50S ribosomal sub-unit of susceptible microorganisms and suppresses protein synthesis. Erythromycin is bacteriostatic and bactericidal depending on its concentration and the type of organism.
	Read more about Erythromycin
2	Tretinoin UNII 5688UTC01R - TRETINOIN
	Tretinoin decreases cohesiveness of follicular epithelial cells resulting in decreased microcomedone formation. Additionally, tretinoin stimulates mitotic activity and increased turnover of follicular epithelial cells, causing extrusion of the comedones.
	Read more about Tretinoin

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
D10AF52	Erythromycin, combinations	D Dermatologicals → D10 Anti-acne preparations → D10A Anti-acne preparations for topical use → D10AF Antiinfectives for treatment of acne
Discover more medicines within D10AF52

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1777057
FR	Base de données publique des médicaments	61381765
HK	Department of Health Drug Office	43673
TN	Direction de la Pharmacie et du Médicament	14303011